SAGE Sage Therapeutics, Inc EV/EBITDA Multiple

Symbol and logo of brand sagerx.com (SAGE)

The price action for Sage Therapeutics, Inc. (SAGE) reflects an EV/EBITDA of . Sage Therapeutics, Inc. (SAGE) specializes in the therapy of severe mental disorders, leveraging an extensive development pipeline to mitigate patent threats. Its high standing within the scientific community contrasts with the shareholders' pragmatic approach to product monetization. The brand is recognized as a pioneer in the treatment of postpartum depression, securing exceptional trust among practicing physicians.

SAGE (Sage Therapeutics Inc) Business Value to Operating Income Before Depreciation history from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Sage Therapeutics (SAGE)

- current price and projected stock value:
Initial company analysis:SAGE (Sage Therapeutics, Inc.)
Product sample of sagerx.com

This indicator determines the business value of Sage Therapeutics, Inc. (SAGE) by accounting for net debt relative to operating profit before taxes, allowing for an assessment of the asset's real value. The ratio compares the total cost of acquiring the enterprise with its ability to generate cash flow. By analyzing the EV/EBITDA trajectory, an investor can evaluate the commercialization efficiency of the drug Zurzuvae within the context of the pharmaceutical sector's capital intensity.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|EV/EBITDA Multiple SAVA (cassavasciences.com)|Business Value to Operating Income Before Depreciation ASRT|Coya Therapeutics Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vistagen.com VTGN|Ovid Therapeutics Inc. (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Acumen Pharmaceuticals, Inc (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc.|Alterity Therapeutics (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|PEPG - Company Value to EBITDA|EV/EBITDA Multiple JUNS (Jupiter Neurosciences, Inc.)|RLMD - Enterprise Value to EBITDA Ratio|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Grace Therapeutics (GRCE)|AIFF: EV/EBITDA Multiple|ANEW Medical, Inc. (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd.|RVPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MTVA|EV/EBITDA Multiple NeurAxis (NRXS)|Helius Medical Technologies, Inc. - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio, Inc. (PASG)|Neuphoria - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NERV (Minerva)|ATHA: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ADXN|Enterprise Value to EBITDA Ratio ALZN|Company Value to EBITDA Cyclerion Therapeutics CYCN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|EV/EBITDA Multiple Pasithea Therapeutics Corp (KTTA)|Cortigent, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Avenue Therapeutics ATXI|BCLI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CARA (Cara Therapeutics)|Chromocell Therapeutics Corporation (CHRO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Eliem Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ITCI|Company Value to EBITDA longboardpharma.com LBPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Marinus (MRNS)|Enterprise Value to Operating Income Before Depreciation Ratio NKGN|EV/EBITDA Multiple NRBO (NeuroBo)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)